130,700 Shares in Roivant Sciences Ltd. $ROIV Purchased by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System purchased a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 130,700 shares of the company’s stock, valued at approximately $3,620,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of ROIV. Goldman Sachs Group Inc. grew its position in Roivant Sciences by 15.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock worth $24,553,000 after buying an additional 324,764 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Roivant Sciences by 1.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after acquiring an additional 34,341 shares during the last quarter. American Century Companies Inc. raised its position in shares of Roivant Sciences by 1.9% during the second quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock worth $1,010,000 after purchasing an additional 1,689 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Roivant Sciences by 149.9% in the second quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock worth $129,000 after buying an additional 6,879 shares during the period. Finally, M&T Bank Corp boosted its holdings in shares of Roivant Sciences by 10.2% in the second quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock worth $144,000 after buying an additional 1,181 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ROIV has been the topic of several research analyst reports. Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Sanford C. Bernstein initiated coverage on shares of Roivant Sciences in a research note on Friday, March 20th. They issued an “outperform” rating and a $35.00 price objective for the company. Citigroup upped their target price on Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, May 21st. TD Cowen lifted their price target on shares of Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Finally, Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a research note on Thursday, May 21st. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $33.59.

Insider Activity

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total value of $6,632,000.00. Following the completion of the sale, the chief executive officer owned 1,613,063 shares in the company, valued at approximately $53,489,169.08. This trade represents a 11.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Jennifer Humes sold 13,538 shares of Roivant Sciences stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $28.37, for a total value of $384,073.06. Following the sale, the chief accounting officer directly owned 84,191 shares in the company, valued at $2,388,498.67. The trade was a 13.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 903,312 shares of company stock valued at $27,437,883. Insiders own 10.80% of the company’s stock.

Roivant Sciences Stock Up 0.1%

Shares of NASDAQ ROIV opened at $34.07 on Friday. Roivant Sciences Ltd. has a 12 month low of $10.70 and a 12 month high of $34.68. The company has a market cap of $24.51 billion, a P/E ratio of -56.78 and a beta of 1.13. The business’s 50 day moving average is $29.66 and its two-hundred day moving average is $26.77.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.57. The business had revenue of $2.52 million for the quarter, compared to the consensus estimate of $3.41 million. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. During the same quarter last year, the company posted ($0.29) earnings per share. Sell-side analysts expect that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.